Identification and analysis of dihydrofolate reductase alleles from Plasmodium falciparum present at low frequency in polyclonal patient samples

American Journal of Tropical Medicine and Hygiene

Volumn 61, Issue 1, 1999, Pages 131-140

  Mookherjee, Somnath ^a   Howard, Vincent ^a   Nzila Mouanda, Alexis ^b   Watkins, William ^b   Sibley, Carol Hopkins ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ANTIMALARIAL AGENT; CHLORCYCLOGUANIL; CHLOROQUINE; CLOCIGUANIL; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROPTEROATE SYNTHASE; FANSIDAR; PYRIMETHAMINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION SYSTEM; GENE FREQUENCY; NONHUMAN; PLASMODIUM FALCIPARUM; POINT MUTATION; PREVALENCE; SACCHAROMYCES CEREVISIAE;

EID: 0032799545     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.61.131     Document Type: Article

References (62)

1. Hitchings GS, Burchall JJ, 1965. Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv Enzymol 27: 417-468.
2. Peters W, 1987. Chemotherapy and Drug Resistance in Malaria. Second edition. London: Academic Press.
3. Hyde JE, 1990. The dihydrofolate reductase-thymidylate synthase gene in the drug resistance of malaria parasites. Pharmacol Ther 48: 45-59.
4. Canfield, CJ, Milhous WK, Ager AL, Rossan RN, Sweeney TR, Lewis NJ, Jacobus DP, 1993. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 49:121-126.
5. Milhous WK, Weatherly NF, Bowdre JH, Desjardins RE, 1985. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother 27: 525-530.
6. Winstanley PA, Mberu EK, Szwandt IS, Breckenridge AM, Watkins WM, 1995. In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother 39: 948-952.
7. White NJ, 1992. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 30: 571-585.
8. White NJ, Olliaro PL, 1996. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 12: 399-401.
9. Wirth DF Cattani L, 1997. Winning the war against malaria. Technol Rev 100: 52-61.
10. Nzila-Mouanda A, Eberu EK, Sibley CH, Winstanley PA, Watkins WM, 1998. Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in dihydrofolate reductase domain. Antimicrob Agents Chemother 42: 164-169.
11. Peterson DS, Walliker D, Wellems TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85: 9114-9118.
12. Peterson DS, Milhous WK, Wellems TE, 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87: 3018-3022.
13. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565-568.
14. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176: 1590-1596.
15. Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176: 1590-1596.
16. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda H, Tanner M, Watkins WM, Sims PFG, Hyde JE, 1997. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 89: 161-177.
17. Warhurst DC, 1997. Drug-resistant malaria: laboratory and field investigations. J Pharm Pharmacol 2: 3-7.
18. Cowman AF, 1997. The mechanisms of drug action and resistance in malaria. Mol Genet Drug Resist 3: 221-246.
19. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ, 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 85: 9109-9113.
20. Curtis J, Duraisingh MT, Trigg JK, Mbwana H, Warhurst DC, Curtis CF, 1996. Direct evidence that asparagine at position 108 of the Plasmodium falciparum dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania. Trans R Soc Trop Med Hyg 90: 678-680.
21. Jelinek T, Proll S, Hess F, Kabagambe G, von Sonnenburg F, Loscher T, Kilian AH, 1996. Geographic differences in the sensitivity of a polymerase chain reaction for the detection of Plasmodium falciparum infection. Am J Trop Med Hyg 55: 647-651.
22. Jelinek T, Renn AM, Curtis J, Duraisingh MT, Lemnge MM, Mhina J, Bygbjerg IC, Warhurst DC, 1997. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimetharriine resistance. Trop Med Int Health 2: 1075-1079.
23. Curtis J, Duraisingh MT, Warhurst DC, 1998. In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. J Infect Dis 177: 1429-1433.
24. de Pecoulas PE, Basco LK, LeBras J, Mazabraud A, 1996. Association between antifol resistance in vitro and DBFR gene point mutation in Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg 90: 181-182.
25. Sirawarapom W, Sathitkul T, Sirawarapom R, Yuthavong Y, Santi DV, 1997. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 94:1124-1129.
26. Sirawarapom W, Yongkiettrakul S, Sirawarapom R, Yuthavong Y, Santi DV, 1997. Plasmodium falciparum: asparagine mutant at residue 108 of dihydrofolate reductase is an optimal antifolate-resistant single mutant. Exp Parasitol 87: 245-252.
27. Tanaka M, Gu HM, Bzik DJ, Li WB, Inselburg J, 1990. Mutant dihydrofolate reductase-thymidylate synthase genes in pyrimethamine-resistant Plasmodium falciparum with polymorphic chromosome duplications. Mol Biochem Parasitol 42: 83-91.
28. Hekmat-Nejad M, Lee PC, Rathod PK, 1997. Plasmodium falciparum: direct cloning and expression of pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase domains. Exp Parasitol 85: 303-305.
29. Hekmat-Nejad M, Rathod PK, 1997. Plasmodium falciparum: kinetic interactions of YvIR99210 with pyrimethamine-sensitive and pyrimethamine-resistant dihydrofolate reductase. Exp Parasitol 87: 222-228.
30. Watkins WM, Mberu EK, Winstanley PA, Plowe CV, 1997. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13: 459-464.
31. Reeder JC, Rieckmann KH, Genton B, Lorry K, Wines B, Cowman AF, 1996. Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am J Trop Med Hyg 55: 209-213.
32. Basco LK, Ringwald P, 1998. Molecular epidemiology of malaria in Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg 58: 369-373.
33. Cortese JF, Plowe CV, 1998. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol Biochem Parasitol 94: 205-214.
34. Durand R, Ramiliarisoa O, Secardin Y, Eldin de Pecoulas P, Basco LK, Le Bras J, 1997. DHFR gene point mutation as a predictor of Plasmodium falciparum resistance to cycloguanil in malaria cases from Africa imported to France. Trans R Soc Trop Med Hyg 91: 460-461.
35. Amukoye E, Winstanley PA, Watkins WM, Snow RW, Hatcher J, Mosobo M, Ngumbao E, Lowe B, Ton M, Minyiri G, Marsh K, 1997. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother 41: 2261-2264.
36. Basco LK, de Eldin PEP, Wilson CM, Le Bras J, Mazabraud A, 1995. Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol 69:135-138.
37. Basco LK Le Bras J, Rhoades Z, Wilson CM, 1995. Analysis of pfmdrI and drug susceptibility in fresh isolates of Plasmodium falciparum from sub-Saharan Africa. Mol Biochem Parasitol 74:157-166.
38. de Pecoulas PE, Abdallah B, Dje MK, Basco LK, Le Bras J, Mazzabraud A, 1995. Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates. Mol Cell Probes 9: 391-397.
39. Laserson KF, Petralanda I, Hamlin DM, Almera R, Fuentes M, Carrasquel A, Barker Jr RH, 1994. Use of the polymerase chain reaction to directly detect malaria parasites in blood samples from the Venezuelan Amazon. Am J Trop Med Hyg 50: 169-180.
40. Parzy D, Doerig C, Pradines B, Rico A, Fusai T, Doury JC, 1997. Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am J Trop Med Hyg 57: 646-650.
41. Zolg JW, Plitt JR, Chen G-X, Palmer S, 1989. Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 36: 253-262.
42. Zolg JW, Chen GX, Plitt JR, 1990. Detection of pyrimethamine resistance in Plasmodium falciparum by mutation-specific polymerase chain reaction. Mol Biochem Parasitol 39: 257-265.
43. Duraisingh MT, Curtis J, Warhurst DC, 1998. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 89: 1-8.
44. Huang T, Barclay BJ, Kalman TI, von Borstel RC, Hastings PJ, 1992. The phenotype of a dihydrofolate reductase mutant in Saccharomyces cerevisiae. Gene 121: 167-171.
45. Wooden JM, Hartwell LH, Vasquez B, Sibley CH, 1997. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol Biochem Parasitol 85: 25-40.
46. Sibley CH, Brophy VH, Cheesman S, Hamilton KL, Hankins EG, Wooden JM, Kilbey B, 1997. Yeast as a model system to study drugs effective against apicomplexan proteins. Methods 13: 190-207.
47. Sherman F, Fink GR, Lawrence CW, 1979. Methods in Yeast Genetics. Cold Spring Harbor, NY: Cold Spring Harbor Press.
48. Wooden JM, Gould EE, Paull AT, Sibley CH, 1992. Plasmodium falciparum: a simple polymerase chain reaction method for differentiating strains. Exp Parasitol 74: 207-212.
49. Peterson DS, di Santi SM, Povoa M, Calvosa VS, do Rosario VE, Wellms TE, 1991. Prevalence of the dihydrofolate reductase Asn-108 mutation as the basis for pyrimethamine-resistant falciparum malaria in the Brazilian Amazon. Am J Trop Med Hyg 45: 492-497.
50. Sikorski RS, Hieter P, 1989. A system or shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122: 19-27.
51. Christianson TW, Sikorski RS, Dante M, Shero JH, Hieter P, 1992. Multifunctional yeast high-copy-number shuttle vectors. Gene 110: 119-122.
52. Lagosky PA, Taylor GR, Haynes RH, 1987. Molecular characterization of the Saccharomyces cerivisiae dihydrofolate reductase gene (DFR 1). Nucleic Acids Res 15: 10355-10371.
53. Bzik DJ, Li WB, Horii T, Inselburg J, 1987. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA 84: 8360-8364.
54. Ito H, Fukuda Y, Murata K, Kimura A, 1983. Transformation of intact yeast cells treated with alkali cations. J Bacteriol 153: 163-168.
55. Watkins WM, Marsh K, 1997. Malaria in east Africa. J Pharm Pharmacol 2: 9-12.
56. Winstanley P, Watkins W, Muhia D, Szwandt S, Amukoye E, Marsh K, 1997. Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg 91: 322-327.
57. de Pecoulas PE, Tahar R, Ouatas T, Mazabraud A, Basco LK, 1998. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol 92: 265-273.
58. Cortese JF, Plowe CV, 1998. Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol Biochem Parasitol 94: 205-214.
59. Heym B, Honore N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs Jr WR, van Embden JD, Grosset JH, Cole ST, 1994. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344: 293-298.
60. Zindrou S, Dung NP, Sy ND, Skold O, Swedberg G, 1996. Plasmodium falciparum: mutation pattern in the dihydrofolate reductase thymidylate synthase genes of Vietnamese isolates, a novel mutation, and coexistence of two clones in a Thai patient. Exp Parasitology 84: 56-64.
61. Kimura M, Kaneko O, Inoue A, Ishii A, Tanabe K, 1995. Amplification by polymerase chain reaction of Plasmodium falciparum DNA from Giemsa-stained thin blood smears. Mol Biochem Parasitol 70: 193-197.
62. Warhust DC, Awad El Kariem FM, Miles MA, 1991. Simplified preparation of malarial blood samples for polymerase chain reaction. Lancet 337: 303-304.